

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Udo Bickers et al.

Application No.: 10/810,211

Confirmation No.: 8656

Filed: March 26, 2004

Art Unit: 1614

For: USE OF HYDROXYAROMATIC
COMPOUNDS AS SAFENERS

Examiner: C. A. Brown

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicant(s) hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicant(s) have become aware of the following documents, cited during the prosecution of a Japanese application which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(d) and (e)(1), hereby submit(s) these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08.

Citation CA (Xiangyu, S. et al., Chemical Reagents, Vol. 4, No. 4, page 196, 1982) discloses a gallic acid methyl ester of formula IV, methyl 3,5-diacetoxy-4-hydroxybenzoate, in the left column (formula on the right, R=CH₃) as a synthetic intermediate.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information

exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicant(s) understand(s) the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed after the mailing date of a Final Office Action or Notice of Allowance, whichever occurred first, but on or before payment of the Issue Fee (37 CFR 1.97(d)). Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered.

I hereby certify, pursuant to 37 CFR 1.97(e)(1), that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Please charge our Credit Card in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 09879-00043-US.

Dated: August 13, 2010

Respectfully submitted,

Electronic signature: /Liza D. Hohenschutz/
Liza D. Hohenschutz
Registration No.: 33,712
CONNOLLY BOVE LODGE & HUTZ LLP
1007 North Orange Street
P. O. Box 2207
Wilmington, Delaware 19899-2207
(302) 658-9141
(302) 658-5614 (Fax)
Attorney for Applicant

798242